MISSION Therapeutics Company
Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylatingenzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
Technology:
Cancer
Industry:
Mitochondrial Dynamics
Headquarters:
United Kingdom
Founded Date:
2011
Employees Number:
11-50
Funding Status:
Late Stage Venture
Estimated Revenue:
$10M to $50M
Register and Claim Ownership